Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
NYSE:PBH
Price:
70.5905 USD
0.38%
Market Closed
Updated:
May 10, 2024
Prestige Consumer Healthcare Inc
Stock-Based Compensation
|
Prestige Consumer Healthcare Inc
Stock-Based Compensation Peer Comparison
Comparables:
JNJ
BMY
PFE
MRK
LLY
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
Stock-Based Compensation
$12.9m
|
CAGR 3-Years
18%
|
CAGR 5-Years
10%
|
CAGR 10-Years
11%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$529m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$525m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$656.7m
|
CAGR 3-Years
27%
|
CAGR 5-Years
18%
|
CAGR 10-Years
16%
|
See Also
What is Prestige Consumer Healthcare Inc's Stock-Based Compensation?
Stock-Based Compensation
12.9m
USD
12.9m
USD
Based on the financial report for Dec 31, 2023, Prestige Consumer Healthcare Inc's Stock-Based Compensation amounts to 12.9m USD.
What is Prestige Consumer Healthcare Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
11%
11%
Over the last year, the Stock-Based Compensation growth was 13%. The average annual Stock-Based Compensation growth rates for Prestige Consumer Healthcare Inc have been 18% over the past three years , 10% over the past five years , and 11% over the past ten years .
You don't have any saved screeners yet
